Standout Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positi... 2016 2026 2019 2022 1.2k
  1. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (2016)
    Massimo Cristofanilli, Nicholas C. Turner et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 14 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

Probiotic neoantigen delivery vectors for precision cancer immunotherapy
2024 StandoutNature
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
2024 Standout
1 intermediate paper

Works of Yuqiu Jiang being referenced

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy
2021
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout

Author Peers

Author Last Decade Papers Cites
Yuqiu Jiang 1542 1357 829 26 2.3k
Katarína Petráková 2074 1351 962 64 2.7k
Amrita Desai 1292 1088 355 35 2.3k
Judy Dering 2155 1294 895 40 3.5k
Jake June-Koo Lee 1044 985 836 38 2.8k
Mónica V. Estrada 1331 653 901 24 2.4k
Steven R. Olsen 3008 849 701 23 3.9k
Ben O’Leary 1614 1613 1263 36 2.6k
Uzma Asghar 1544 1284 479 25 2.3k
Ilenia Migliaccio 1215 797 563 63 2.0k
Jeffry L. Dean 1137 1003 357 25 1.9k

All Works

Loading papers...

Rankless by CCL
2026